Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068470 · ClinicalTrials.gov registry record
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
A clinical trial, sponsored by Loma Linda University.
- Terminated
- Registry status
- 11
- Enrollment target
NCT01068470 is a clinical trial that was terminated before completion, run by Loma Linda University. The registered enrollment target is 11 participants.
The verdict
NCT01068470 was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068470
The ClinicalTrials.gov registry entry for NCT01068470 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01068470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01068470 about?
NCT01068470 is a clinical study titled "Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy". Therapy with Interleukin-2 stimulates lymphocytes in humans to become Lymphokine-activated Killer cells (LAK). This study will determine if these killer cells are able to kill certain standard cell-lines in the laboratory.
What is the current status of trial NCT01068470?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2009-11. Estimated completion is 2012-03.
Who is sponsoring clinical trial NCT01068470?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.